Tirzepatide

Scientific Overview

Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in incretin receptor signaling research.

Mechanism focus

Engages both GIP and GLP-1 receptors. Research compares its receptor binding and signaling with single-receptor agonists.

Research Use Cases

• Dual-incretin receptor pharmacology
• Dual-incretin receptor comparison studies
• Head-to-head incretin agonist studies (SURPASS vs semaglutide)
• Metabolic syndrome biomarker panels

Use-Case Study Notations

• Case-study notation: SURPASS-2 compared tirzepatide with semaglutide for glycemic endpoints in type 2 diabetes.
• Dual-agonist design requires careful peptide identity testing (MS/HPLC).

Selected Studies

1. 01 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesPubMed 34170647
2. 02 Tirzepatide Once Weekly for the Treatment of ObesityPubMed 35658024
3. 03 Tirzepatide for Obesity Treatment and Diabetes PreventionPubMed 39536238
4. 04 Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity ManagementPubMed 36750526
5. 05 Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development programPubMed 36478180

Related compounds

Semaglutide · Retatrutide · AOD-9604